| NCT ID | NCT07504146 |
| Status | Recruiting |
| Phase | — |
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
| Condition | CPPD - Calcium Pyrophosphate Deposition Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2027-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2024-10-30 with a primary completion date of 2027-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study at IRCCS Galeazzi - Sant'Ambrogio Hospital involves patients with gout, CPPD, and osteoarthritis as a control group. Patients will receive routine care with regular clinical, laboratory, and imaging assessments every six months, alongside urgent visits as needed. The study aims to understand crystal deposits in joints and blood vessels and monitor their progression over time, assessing how these deposits respond to standard treatments and if they are associated with cardiovascular complications. Data will be collected from medical records over a follow-up period of up to 10 years, offering long-term insights into disease impact and treatment effectiveness.
Eligibility Criteria
The inclusion criteria for CPPD patients are: * Patients diagnosed with CPPD disease according to the ACR/EULAR 2023 classification criteria. * Patients with evidence of asymptomatic CPPD on US or X-rays (not meeting the classification criteria) according to validated imaging definitions. * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee. The inclusion criteria for gout patients are: * Patients diagnosed with gout according to the ACR/EULAR 2015 classification criteria. * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee. The inclusion criteria for disease controls are: * A diagnosis of OA according to ACR classification criteria * No evidence of uric acid or calcium pyrophosphate deposits on US * Uric acid \< 6 mg/dL * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee The exclusion criteria for gout/CPPD patients are: * Known history of other inflammatory arthropathies * Unable to provide informed consent, according to requirements of local IRB/ethics committee. The exclusion criteria for disease controls are: * Known history of other inflammatory arthropathies * Unable to provide informed consent, according to requirements of local IRB/ethics committee.
Contact & Investigator
Georgios Filippou, MD
PRINCIPAL INVESTIGATOR
Università degli Studi di Milano / IRCCS Ospedale Galeazzi-Sant'Ambrogio
Frequently Asked Questions
Who can join the NCT07504146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CPPD - Calcium Pyrophosphate Deposition Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07504146 currently recruiting?
Yes, NCT07504146 is actively recruiting participants. Contact the research team at georgios.filippou@grupposandonato.it for enrollment information.
Where is the NCT07504146 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07504146 clinical trial?
NCT07504146 is sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio. The principal investigator is Georgios Filippou, MD at Università degli Studi di Milano / IRCCS Ospedale Galeazzi-Sant'Ambrogio. The trial plans to enroll 450 participants.